CVS Group: The Antitrust Fog Lifts, and the Vet Chain Bets on Subscriptions
Revenue up 5.9%, a new loyalty tier, and a symbolic UK acquisition — as the CMA overhang finally clears and the industry's labour squeeze eases.
CVSG.L · Earnings Call · 2026-09-24
The fog lifts on the CMA
For two years, the CMA process has been the single biggest cloud over CVS Group, the UK's largest veterinary chain — an antitrust review that froze investment, weighed on sentiment, and capped the multiple. This week, that fog lifted.
We now have certainty following the conclusion of the CMA process with a number of remedies implemented and others in hand.
That is a de-risking event, not a shock: management had been preparing for the detail for six months, so the announcement was about clarity, not surprise.
Chief Veterinary Officer Paul Higgs framed it as a profession-wide reset — and a chance to rebuild the reputational capital a long review tends to erode. “I do think that there is work to be done as a profession together to rebuild trust, to make sure that we are creating that best environment to be seen as the providers of great veterinary care.” — Paul Higgs, Chief Veterinary Officer · 2026-09-24 That is precisely where the freshly unified care of CVS brand identity, plus a newly created Chief Client Officer seat, come in.
A subscription answer to a footfall problem
The most revealing part of the call was the demand diagnosis. CVS grew revenue 5.9% to £712.8m and adjusted EBITDA 5.1% to £141.5m — solid, but with a sharp split underneath. Where animals are ill or injured, clients spend. Where it is routine, they don't. “Footfall is still a challenge across the profession, but it's mixed across our practices” — Richard William Fairman, CEO · 2026-09-24, CEO Richard Fairman said, noting the soft spot sits squarely in "routine preventative treatments." The footfall problem is, at root, a consumer confidence problem — UK-specific, and worse than the backdrop in Australia.
The response is company-unique and topped CVS's own keyword list this quarter: Healthy Pet Club Advanced, launched 1 July. “So Healthy Pet Club Advanced, we launched on the 1st of July, and we've seen good growth in that scheme.” — Richard William Fairman, CEO · 2026-09-24 A higher monthly fee buys unlimited consultations, and the early read is that it lifts engagement and spend per client rather than cannibalising existing tiers — a hybrid of loyalty economics and cross selling. It echoes how other consumer franchises deepen brand awareness and member stickiness through paid membership.
The proof of the underlying split is in the divisions: laboratory revenue grew 25%, and referral hospitals were strong, because sick animals do get treated. That mix shift — advanced care up, routine prevention soft — is the thing to watch.
Quality of earnings — the RDEC question
Not all of the EBITDA growth is operational. Deutsche's Kane Slutzkin pressed whether the UK R&D tax credit (RDEC) and a related provision release explained "maybe half" of the growth. CFO Robin Alfonso pushed back: RDEC recognition was £15.7m versus £15.1m prior, so essentially consistent. But he conceded “we take quite a prudent approach to RDEC claims... it was right that we reduced that provision.” — Robin Alfonso, CFO · 2026-09-24
This is the small-cap analogue of a theme running loudly through this season globally. Consumer names CBRL, Costco, KMD Brands and MillerKnoll all flagged one-off tariff refund-style windfalls flattering reported earnings. CVS's version is a UK tax credit plus a provision unwind. In both cases the analyst question is identical: how much of the beat recurs?
The UK M&A tap reopens
Capital allocation is where the mood genuinely changed. After six acquisitions in Australia (£43.3m, 14 sites), CVS exchanged contracts on its first U.K. acquisition in some time — a two-site, high-quality practice for roughly £15m, at a multiple management says is accretive to the group. “we've made it clear that we were keen to return to U.K. acquisitions where we saw accretive opportunities.” — Richard William Fairman, CEO · 2026-09-24 Management will spend past its £50m earmark if returns justify, and will temporarily breach its 2x leverage ceiling for the right deal — a sign of confidence in the pipeline.
Crucially, the labour constraint that has squeezed the whole sector is loosening. “we are seeing a consistent reduction in our vacancy rates for vets” — Paul Higgs, Chief Veterinary Officer · 2026-09-24 — a genuine margin tailwind after years of wage inflation and the £8m national-insurance hit.
The bottom line
CVS is a roughly £830m-cap, cash-generative compounder emerging from a regulatory twilight. Like-for-like growth of 2.1% for FY26 sits well below the 4–8% medium-term target, but August returned to first-half levels and management guided 3–4% for the near term, with a self-help plan — pricing, a subscription tier, a rebuilt brand, and a returning M&A pipeline on two continents — rather than a macro bet. A retiring CEO adds a governance variable to watch. But the de-risking is real, and the subscription pivot is the fresh, company-specific signal worth tracking.